On May 30, 2025, Goldman Sachs analyst Kate McShane initiated coverage on DexCom (DXCM, Financial), a leading player in the continuous glucose monitoring sector. The firm has assigned a "Buy" rating to the stock, indicating a positive outlook for its performance.
The decision by Goldman Sachs to cover DXCM comes at a crucial time, as the company continues to innovate and expand its product line within the healthcare market. The "Buy" rating suggests strong confidence in DexCom's future growth potential and market position.
While no price target has been set at this time, the initiation of coverage underscores Goldman Sachs' belief in the stock's potential for upward movement. Investors are encouraged to keep an eye on DXCM as it progresses in the competitive healthcare industry.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 25 analysts, the average target price for DexCom Inc (DXCM, Financial) is $99.73 with a high estimate of $115.00 and a low estimate of $82.00. The average target implies an upside of 15.99% from the current price of $85.98. More detailed estimate data can be found on the DexCom Inc (DXCM) Forecast page.
Based on the consensus recommendation from 27 brokerage firms, DexCom Inc's (DXCM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for DexCom Inc (DXCM, Financial) in one year is $164.82, suggesting a upside of 91.7% from the current price of $85.98. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the DexCom Inc (DXCM) Summary page.
